NCT06969833 2026-03-17
BCB-OVAIRE
Centre Oscar Lambret
Phase NA Recruiting
Clinical Trials
41 trialsNCT05231122 2026-03-16
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT06483048 2026-03-16
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
Phase 1 Recruiting
NCT03968406 2026-03-11
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07460180 2026-03-10
PROOV
The Netherlands Cancer Institute
Phase 1/2 Recruiting
NCT04575935 2026-03-05
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT05574673 2026-02-27
HERO
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Recruiting
NCT03862677 2026-02-13
IMPrOVE
Leiden University Medical Center
Recruiting
NCT05460000 2026-02-12
N-Plus
North Eastern German Society of Gynaecological Oncology
Phase 2 Recruiting
NCT05415709 2026-02-11
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05465941 2026-02-09
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Mayo Clinic
Phase 2 Recruiting
NCT03296826 2026-02-03
Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Recruiting
NCT06290193 2026-01-15
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06856499 2026-01-09
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
University of Colorado, Denver
Phase 1 Recruiting
NCT05080946 2026-01-08
Using Aspirin to Improve Immunological Features of Ovarian Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT06855706 2026-01-06
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
Roswell Park Cancer Institute
Phase NA Recruiting
NCT07285044 2025-12-22
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT06710548 2025-12-17
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT06342986 2025-11-12
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Recruiting
NCT05287451 2025-11-05
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT06617923 2025-10-27
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06295965 2025-10-15
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
University of Washington
Recruiting
NCT03604315 2025-10-14
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05009082 2025-09-10
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Phase 3 Recruiting
NCT04469764 2025-07-29
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT07022535 2025-07-02
PRESELECT-0
The University of Hong Kong
Phase 2 Recruiting
NCT07023484 2025-07-02
Preselect-1
The University of Hong Kong
Phase 2 Recruiting
NCT05071937 2025-06-22
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT05920798 2025-06-22
FRAPPE
Mayo Clinic
Phase 1/2 Recruiting
NCT05429970 2025-05-18
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT04919629 2025-05-11
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT00005095 2025-02-28
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Northwestern University
Recruiting
NCT03976999 2025-02-12
BCBOvaire
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Recruiting
NCT04701645 2025-02-05
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
Phase 1 Recruiting
NCT06638593 2024-10-15
MIRRORS-FROZEN
Royal Surrey County Hospital NHS Foundation Trust
Phase NA Recruiting
NCT04811703 2024-09-19
PIPACOVA
Hospices Civils de Lyon
Phase 1 Recruiting
NCT06445621 2024-06-06
FOLL-OV
Uppsala University Hospital
Recruiting
NCT06420973 2024-05-20
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05080556 2024-04-12
ACTOv
University College, London
Phase 2 Recruiting
NCT05912972 2023-06-22
Development and Management of Registry in Patients With Gynecologic Cancer in Korea
Asan Medical Center
Recruiting
NCT04834544 2021-05-03
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
Peking University Third Hospital
Phase 2 Recruiting